The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Immunotherapy for lymphoma: how is it impacting the treatment course?
Adam Olszewski, MD, Brown University, Providence, RI, discusses the ongoing interest in immunotherapy for the treatment of lymphoma, which offers a chemotherapy-free option for patients. He highlights that the introduction of these agents could lead to personalized therapy for patients with different clinical characteristics or desires. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that, you know, for lymphoma, there was this year no great or monumental shift in the strategy. I think the ongoing interest in immunotherapy continues, and both from the perspective of aggressive lymphomas, where we are starting to see more and more studies investigating chemotherapy-free approaches right now among older patients. But I believe that we are reaching the point or reaching the point where we can start to offer these treatments to all patients with diffuse large B-cell lymphoma potentially with suitable safety measures, as well as newer immunotherapy-based combinations with follicular lymphoma, such as the introduction of epcoritamab and R-squared, both broaden now the range of options that we have, and maybe perhaps will lead to us doing some more personalized therapy for patients with different clinical characteristics or different desires in terms of the treatment intensity, treatment frequency...
I think that, you know, for lymphoma, there was this year no great or monumental shift in the strategy. I think the ongoing interest in immunotherapy continues, and both from the perspective of aggressive lymphomas, where we are starting to see more and more studies investigating chemotherapy-free approaches right now among older patients. But I believe that we are reaching the point or reaching the point where we can start to offer these treatments to all patients with diffuse large B-cell lymphoma potentially with suitable safety measures, as well as newer immunotherapy-based combinations with follicular lymphoma, such as the introduction of epcoritamab and R-squared, both broaden now the range of options that we have, and maybe perhaps will lead to us doing some more personalized therapy for patients with different clinical characteristics or different desires in terms of the treatment intensity, treatment frequency. So I’m really excited to bring these questions back to my patients and see how we work out to really what treatments are best for them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
